During the corresponding time, Volitionrx Limited saw a revenue deteriorated by -1.97 % year on year, sequentially revenue fell by -59.53 %. While revenue at the Volitionrx Limited's corporate clients
Volitionrx Limited's Comment on Sales, Marketing and Customers
Volition operates in the diagnostics and liquid biopsy sectors, collaborating with approximately ten leading companies for its Nu.Q® and Capture-Seq™ technologies. In the veterinary market, Volition holds agreements with Heska (now an Antech Company) for exclusive worldwide rights to sell the Nu.Q® Vet Cancer Test at the point of care for companion animals, and with IDEXX to access customers through IDEXX’s global reference laboratory network. The Nu.Q® Vet Cancer Test has been launched in the UK, Ireland, and Japan via distributors including the Veterinary Pathology Group, Nationwide Laboratories, and Fujifilm Vet Systems. Fujifilm Vet Systems has also entered an automation agreement to utilize Volition’s ChLIA test on the IDS i10® automated analyzer platform. Volition is also marketing its CE-marked Nu.Q® NETs test, either directly or in partnership with Immunodiagnostic Systems, targeting clinical institutions for applications involving NETosis, with initial sales recorded in Europe in early 2025. Other customers and markets associated with Volition include Hologic and Revvity.
Volitionrx Limited’s Comment on Sales, Marketing and Customers
Volition operates in the diagnostics and liquid biopsy sectors, collaborating with approximately ten leading companies for its Nu.Q® and Capture-Seq™ technologies. In the veterinary market, Volition holds agreements with Heska (now an Antech Company) for exclusive worldwide rights to sell the Nu.Q® Vet Cancer Test at the point of care for companion animals, and with IDEXX to access customers through IDEXX’s global reference laboratory network. The Nu.Q® Vet Cancer Test has been launched in the UK, Ireland, and Japan via distributors including the Veterinary Pathology Group, Nationwide Laboratories, and Fujifilm Vet Systems. Fujifilm Vet Systems has also entered an automation agreement to utilize Volition’s ChLIA test on the IDS i10® automated analyzer platform. Volition is also marketing its CE-marked Nu.Q® NETs test, either directly or in partnership with Immunodiagnostic Systems, targeting clinical institutions for applications involving NETosis, with initial sales recorded in Europe in early 2025. Other customers and markets associated with Volition include Hologic and Revvity.
Sources:
Volitionrx Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Volitionrx Limited’s corporate clients.
For your research, we’ve provided 9 tables on Volitionrx Limited corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
